Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Chris W. who wrote (1902)	2/11/1999 10:44:00 PM
From: Steve Harmon	Respond to of 2742

Cistron has... 2 investment bankers. 1 PR Firm. $14.2 million in cash. No debt. No burn. $30 million potential deal with a major pharm. Pasteur Merieux bought 1.3 million shares of Cistron stock for .75 A 4 million share buyback for support(Not being used) Very well paid manager. And shareholder value has INCREASED $0 since the IMNX deal 2 years ago..... What will the Cistron BOD do? The Manager's contract expires on April 30.

To: Chris W. who wrote (1902)	2/21/1999 11:31:00 AM
From: Walter Morton	Respond to of 2742

"For a number of years preceding the litigation settlements, Cistron did not have funding to conduct ongoing research programs. In the fiscal years 1990 through 1997, cumulative research expenditures were $581,000. However, in the first nine months of fiscal 1998 research expenditures were $463,000. Now, through a combination of our own internal research and projects contracted to outside laboratories, we are obtaining data on our technologies which will help us to determine Cistron's future product development directions and to assist us regarding strategic alliances."